"Paxlovid's Limited Impact on Vaccinated COVID-19 Patients Revealed in Study"
TL;DR
A study in the New England Journal of Medicine found that the antiviral drug Paxlovid did not significantly reduce symptom duration for fully vaccinated individuals with at least one risk factor for severe COVID-19. The trial included 1,296 participants and showed no significant difference in symptom alleviation between those who took Paxlovid and those who took a placebo. Experts caution that the findings might not apply to older, high-risk populations and suggest that longer-term studies on Paxlovid are needed to assess its potential benefits, particularly for those at highest risk for disease progression.
- Among fully vaccinated, study shows Paxlovid does not shorten symptoms University of Minnesota Twin Cities
- Paxlovid Fails to Shorten COVID in Standard-Risk and Vaccinated At-Risk Patients Medpage Today
- Predictors of nirmatrelvir–ritonavir receipt among COVID-19 patients in a large US health system | Scientific Reports Nature.com
- Paxlovid is effective against Covid-19, but many people eligible for it are not getting it; it’s fre ... The Lexington Times
Want the full story? Read the original reporting
Read on University of Minnesota Twin Cities